|
FASLG |
Fas ligand |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- Interleukin-4 and Interleukin-13 signaling
- Dimerization of procaspase-8
- FasL/ CD95L signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- FOXO-mediated transcription of cell death genes
- TNFs bind their physiological receptors
|
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
|
FBP2 |
fructose-bisphosphatase 2 |
|
|
|
|
FBXO5 |
F-box protein 5 |
- SCF-beta-TrCP mediated degradation of Emi1
- Regulation of APC/C activators between G1/S and early anaphase
- Phosphorylation of Emi1
- Mitotic Metaphase/Anaphase Transition
- G1/S-Specific Transcription
|
|
|
|
FGR |
FGR proto-oncogene, Src family tyrosine kinase |
- FCGR activation
- Platelet sensitization by LDL
- Neutrophil degranulation
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
|
- Dasatinib
- Fostamatinib
- Zanubrutinib
|
|
|
FHIT |
fragile histidine triad diadenosine triphosphatase |
|
- Adenosine monotungstate
- Ado-P-Ch2-P-Ps-Ado
|
- Small cell lung cancer
- Non-small cell lung cancer
|
|
FLNA |
filamin A |
- Platelet degranulation
- GP1b-IX-V activation signalling
- Cell-extracellular matrix interactions
- RHO GTPases activate PAKs
- OAS antiviral response
|
|
- FG syndrome (FGS); Opitz-Kaveggia syndrome
- Periventricular nodular heterotopia (PVNH)
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
- Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
|
|
FLT3 |
fms related receptor tyrosine kinase 3 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- FLT3 Signaling
- FLT3 Signaling
- STAT5 Activation
- FLT3 mutants bind TKIs
- STAT5 activation downstream of FLT3 ITD mutants
- KW2449-resistant FLT3 mutants
- semaxanib-resistant FLT3 mutants
- crenolanib-resistant FLT3 mutants
- gilteritinib-resistant FLT3 mutants
- lestaurtinib-resistant FLT3 mutants
- midostaurin-resistant FLT3 mutants
- pexidartinib-resistant FLT3 mutants
- ponatinib-resistant FLT3 mutants
- quizartinib-resistant FLT3 mutants
- sorafenib-resistant FLT3 mutants
- sunitinib-resistant FLT3 mutants
- tandutinib-resistant FLT3 mutants
- linifanib-resistant FLT3 mutants
- tamatinib-resistant FLT3 mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Negative regulation of FLT3
- FLT3 signaling through SRC family kinases
- FLT3 signaling through SRC family kinases
- FLT3 signaling by CBL mutants
|
- Sorafenib
- Sunitinib
- XL999
- Tandutinib
- Linifanib
- Lestaurtinib
- Midostaurin
- Ponatinib
- Nintedanib
- Pacritinib
- Tivozanib
- Fostamatinib
- Gilteritinib
- Brigatinib
- Fedratinib
- Amuvatinib
- Quizartinib
- Pexidartinib
- Pralsetinib
|
- Acute myeloid leukemia (AML)
|
|
FMR1 |
fragile X messenger ribonucleoprotein 1 |
|
|
- Premature ovarian failure
- Fragile X Syndrome, including: Fragile X Syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)
|
|
FOXO1 |
forkhead box O1 |
- AKT phosphorylates targets in the nucleus
- Regulation of gene expression in beta cells
- AKT-mediated inactivation of FOXO1A
- Constitutive Signaling by AKT1 E17K in Cancer
- MAPK6/MAPK4 signaling
- Interleukin-4 and Interleukin-13 signaling
- Regulation of localization of FOXO transcription factors
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of cell death genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
|
- Alveolar rhabdomyosarcoma
|
|
FRS2 |
fibroblast growth factor receptor substrate 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Frs2-mediated activation
- Frs2-mediated activation
- Signaling by ALK
- Constitutive Signaling by Aberrant PI3K in Cancer
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- FRS-mediated FGFR2 signaling
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK2 signals through FRS2 and FRS3
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by ALK fusions and activated point mutants
|
|
|
|
FYB1 |
FYN binding protein 1 |
- Generation of second messenger molecules
- Generation of second messenger molecules
- Signal regulatory protein family interactions
|
|
|
|
FZR1 |
fizzy and cell division cycle 20 related 1 |
- Autodegradation of Cdh1 by Cdh1:APC/C
- SCF-beta-TrCP mediated degradation of Emi1
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
- Regulation of APC/C activators between G1/S and early anaphase
- Phosphorylation of Emi1
- Senescence-Associated Secretory Phenotype (SASP)
- Assembly of the pre-replicative complex
- CDK-mediated phosphorylation and removal of Cdc6
- Cyclin A/B1/B2 associated events during G2/M transition
- Cyclin A:Cdk2-associated events at S phase entry
- Transcriptional Regulation by VENTX
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
GAB1 |
GRB2 associated binding protein 1 |
- PI3K Cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PIP3 activates AKT signaling
- GAB1 signalosome
- PI3K events in ERBB2 signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- MET activates PTPN11
- MET activates RAP1 and RAC1
- MET receptor recycling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
|
|
|
|
GAB2 |
GRB2 associated binding protein 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Constitutive Signaling by Aberrant PI3K in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RET signaling
- Interleukin-15 signaling
- Interleukin receptor SHC signaling
- FLT3 Signaling
- FLT3 Signaling
- STAT5 Activation
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
|
|
|
|
GAB3 |
GRB2 associated binding protein 3 |
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
GALNT12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
- Defective GALNT12 causes CRCS1
- O-linked glycosylation of mucins
|
|
|
|
GFAP |
glial fibrillary acidic protein |
- Nuclear signaling by ERBB4
- Chaperone Mediated Autophagy
|
|
|
|
GIT1 |
GIT ArfGAP 1 |
- Ephrin signaling
- Ephrin signaling
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOQ GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Activation of RAC1 downstream of NMDARs
|
|
|
|
GJA1 |
gap junction protein alpha 1 |
- Oligomerization of connexins into connexons
- Transport of connexins along the secretory pathway
- Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
- Gap junction assembly
- Gap junction assembly
- Gap junction degradation
- Regulation of gap junction activity
- Regulation of gap junction activity
- Formation of annular gap junctions
- RHOQ GTPase cycle
- RHOJ GTPase cycle
- SARS-CoV-2 targets PDZ proteins in cell-cell junction
- Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
|
|
- Deafness, autosomal recessive
- Oculodentodigital dysplasia
- Syndactyly
|
|
GJB1 |
gap junction protein beta 1 |
- Oligomerization of connexins into connexons
- Oligomerization of connexins into connexons
- Transport of connexins along the secretory pathway
- Gap junction assembly
|
|
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
|